

**FOR IMMEDIATE RELEASE**

**June 10, 2008**

**Sequella, Inc. Selected to Present  
at the 2008 BIO International Convention**

**ROCKVILLE, MD** – Sequella, Inc. ([www.sequella.com](http://www.sequella.com)) today announced that Alan Klein, Executive Vice President of Corporate Development, will present an overview of the Company's clinical development and drug discovery programs at the 2008 BIO International Convention in San Diego, California. Mr. Klein is scheduled to speak on June 18, 2008 at 3:15 p.m. (Pacific Time) in Room 5B of the San Diego Convention Center.

Founded in 1997, Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for diseases of epidemic potential. Sequella leverages its global influence, infectious disease expertise, and diverse product portfolio to proactively address emerging health threats with significant market opportunity. Sequella currently has 124 issued patents worldwide and an additional 55 patents in review.

The Company's lead drug candidate, SQ109, is completing Phase I clinical trials. This new diamine antibiotic could replace one or more of the current first-line anti-tuberculosis drugs and simplify therapy. SQ109 was granted U.S. FDA Fast Track and FDA/EMEA Orphan Drug Designation in 2007.

The Company's target market for its first commercial products is the \$1.5 billion currently spent on TB diagnostics and drugs. Sequella believes that its novel product pipeline is positioned to capture a significant portion of the worldwide market. With the expected commercialization of the TB Patch diagnostic and SQ109 antibiotic in human studies, the company plans to accelerate the development of its preclinical candidates for select other indications with high unmet needs.

Sequella's pipeline of multifunctional, targeted NCE drug candidates has broad market potential in disease areas with known or potential infectious etiology. Key preclinical programs are focused on new broad-spectrum antibiotics or specific NCEs for systemic fungal infections and other bacterial diseases.

###

**Forward-Looking Statement**

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.

**About BIO**

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. BIO also produces the annual BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

**For More Information Contact: Alicia Moran, Brightline Media, Inc., 703-739-2424 x 110**